Statins in stroke prevention: Present and future

Current Pharmaceutical Design

Volumn 22, Issue 30, 2016, Pages 4638-4644

  Castilla Guerra, Luis ^a   Fernandez Moreno, María del Carmen ^b   Colmenero Camacho, Miguel Angel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Ezetimibe; PCSK9 inhibitors; Primary prevention; Secondary prevention; Statins; Stroke prevention

Indexed keywords

ALIROCUMAB; ATORVASTATIN; CHOLESTEROL; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PROTEIN; PROTEIN INHIBITOR; PROTEIN PCSK9; PROTEIN PCSK9 INHIBITOR; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK; META ANALYSIS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; STROKE;

EID: 84989271455     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160510125229     Document Type: Review

References (49)

1. Feigin VL, Krishnamurthi RV, Parmar P, et al. GBD 2013 Writing Group; GBD 2013 Stroke Panel Experts Group. Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology 2015; 45: 161-76.
2. Berkowitz AL. Stroke and the noncommunicable diseases: A global burden in need of global advocacy. Neurology 2015; 26 (84): 2183-4.
3. Castilla Guerra L, del Carmen Fernández-Moreno M, Marín-Martín J. Factors explaining excess stroke prevalence: the Spanish stroke belt. Stroke 2010; 41: e114.
4. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453-63.
5. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 30; 373: 1849-60.
6. Castilla Guerra L, del Carmen Fernández Moreno M, López Chozas JM, Jiménez Hernández MD. What a internist 2008 Statins in stroke prevention: what an internist should know. Eur J Intern Med 2008; 19: 8-14.
7. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13.000 strokes in 450.000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53.
8. Yaghi S, Elkind MSV. Lipids and cerebrovascular disease research and practice. Stroke 2015; 46: 3322-8.
9. Wang X, Dong Y, Qi X, et al. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 2013; 44: 1833.
10. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 484-93.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4, 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
12. Byington RP, Davis BR, Plehn JF, et al. for the PPP Investigators. The prospective pravastatin pooling (PPP) project. Circulation 2001; 103: 387-92.
13. Heart Protection Collaborative Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
14. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002; 106: 1690-5.
15. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-scandinavian cardiac outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
16. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
17. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010; 121: 143-50.
18. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-6.
19. Ribeiro RA, Ziegelmann PK, Duncan BB, et al. Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175, 000 patients. Int J Cardiol 2013; 166: 431-9.
20. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
21. Goldstein LB, Amarenco P, Szarek M, et al. SPARCL Investigators. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 2008 10; 70: 2364-70.
22. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-236.
23. Huisa BN, Stemer AB, Zivin JA. Atorvastatin in stroke: a review of SPARCL and subgroup analysis. Vasc Health Risk Manag 2010; 6: 229-36.
24. Chaturvedi S, Zivin JA, Breazna A, et al. for the SPARCL investigators. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 2009; 72: 688-94.
25. Goldstein LB, Amarenco P, Lamonte M, et al. SPARCL Investigators. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008; 39: 2444-8.
26. Amarenco P, Benavente O, Goldstein LB, et al. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40: 1405-9.
27. Sillesen H, Amarenco P, Hennerici MG, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke 2008; 39: 3297-302.
28. Amarenco P, Goldstein LB, Szarek M, et al. SPARCL Investigators Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38: 3198-204.
29. Amarenco P, Goldstein LB, Messig M, et al. SPARCL Investigators. Relative and cumulative effects of lipid and blood pressure control in the stroke prevention by aggressive reduction in cholesterol levels trial. Stroke 2009; 40: 2486-92.
30. Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev 2009; (3): CD002091.
31. Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki A, Nezu T. The japan statin treatment against recurrent stroke (J-STARS): a multicentre, randomized, open-label, parallel group study. EBio-Medicine 2015; 2: 1071-8.
32. Hankey GJ. The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Trial: Where to Now? EBioMedicine 2015; 2: 1008-9.
33. Jones PH, Davidson MH, Stein EA. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.
34. Reith C, Armitage J. Management of residual risk after statin therapy. Atherosclerosis 2016; 245: 161-17.
35. Kramer W. Antilipidemic Drug Therapy Today and in the Future. Handb Exp Pharmacol 2015 Sep 2. [Epub ahead of print].
36. Colantonio LD, Bittner V. Managing residual risk after myocardial infarction among individuals with low cholesterol levels. Cardiol Clin 2015; 33: 299-308.
37. De Caterina R, Scarano M, Marfisi R, et al. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010; 55: 198-211.
38. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: (Suppl 2): S1-S45.
39. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
40. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21, 000 subjects from 27 clinical trials. Atherosclerosis 2012; 223: 251-61.
41. Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp (a) lowering drugs. Eur Heart J 2013; 34: 1783-9.
42. Gouni-Berthold I. PCSK9 antibodies: A new class of lipid-lowering drugs. Atheroscler Suppl 2015; 18: 21-7.
43. Lepor NE, Kereiakes DJ. The PCSK9 Inhibitors: A novel therapeutic target enters clinical practice. Am Health Drug Benefits 2015; 8: 483-9.
44. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18.
45. Sabatine MS, Giugliano RP, Wiviott SD, et al. Open-label study of long-term evaluation against ldl cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9.
46. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
47. ClinicalTrials.gov. NCT01764633: Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) (http: //ClinicalTrials.gov/show/NCT01764633).
48. Swiger KJ, Martin SS. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Saf 2015; 38: 519-26.
49. Meschia JF, Bushnell C, Boden-Albala B, et al. American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2014; 45: 3754-832.